Navigation Links
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Date:5/21/2008

ETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study with weight-based ribavirin, there was a higher rate of anemia among patients in the weight-based dosing group (29%) compared to the flat- dosing group (19%). The majority of these cases were mild and responded to dose reductions. Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group.

Additional Safety Information

Relapse of drug addiction/overdose has occurred in patients on PEGINTRON therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy.

Please see important full U.S. prescribing informati
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
4. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Schering-Plough Reports Top-Line Results of the IDEAL Study
7. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
8. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
9. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
10. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
11. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013.  ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Mich., Jan. 23, 2012 Perrigo Company (Nasdaq: PRGO;TASE) announced ... Administration (FDA) an Abbreviated New Drug Application (ANDA) for azelastine ... the owner of the New Drug Application (NDA) of its ... Impax Laboratories, Inc. (Nasdaq: IPXL ), who will ...
... (OTC: PLCSF), a company focused on innovative medical device ... in the CIN-RG trial, the company,s pivotal trial to ... System™ in the prevention of Contrast-Induced Nephropathy (CIN).  This ... regulatory approval by the U.S. Food and Drug Administration ...
Cached Medicine Technology:Perrigo Confirms Filing for Generic Version of Astepro® Nasal Spray and Announcement of Patent Infringement Lawsuit by Meda Pharmaceuticals 2Perrigo Confirms Filing for Generic Version of Astepro® Nasal Spray and Announcement of Patent Infringement Lawsuit by Meda Pharmaceuticals 3First Patient Treated in PLC Systems' RenalGuard® U.S. Pivotal Trial 2First Patient Treated in PLC Systems' RenalGuard® U.S. Pivotal Trial 3
(Date:5/20/2013)... Goodman HealthDay Reporter , , SATURDAY, May 18 ... a better view during colonoscopies may help them miss ... shows. Colonoscopies are the recommended screening tests for ... of men and women in the United States. ... tube with a camera mounted on the end called ...
(Date:5/20/2013)... May 20, 2013 A novel service for ... . The company has been in the field of providing ... will make sure that scholars are able to maintain a ... has three stages and has been priced at $1000. , ... dedicated mentor assigned to the project, who will handle all ...
(Date:5/20/2013)... Hiscall Inc. is pleased to announce the ... devices. The Hiscall app includes past, current and future ... and event alerts. , For many, the mobile ... such as the Hiscall Technology Showcase, enabling users to register ... layout. During and after the event users can access ...
(Date:5/20/2013)... Dana R. Hando knows that nails ... experience in a salon, she has seen nails of different shapes, ... article that explains how this small body part can actually serve ... body. A piece from The Huffington Post explains that ... on early warning signs of medical conditions. , Nails that ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 When developing ... gender and personality, are taken into consideration to help ... Researchers have previously determined that there is a clear ... Doc considers the science behind these studies and others ... Now, a new study exploring the effect weight gain ...
Breaking Medicine News(10 mins):Health News:New Device May Show Doctors More of the Colon 2Health News:New Device May Show Doctors More of the Colon 3Health News:Dissertation Clinic Prescribes Customized Remedy for Researchers 2Health News:According to Dana R. Hando, Nails Help to Illustrate Total Body Health 2Health News:According to Dana R. Hando, Nails Help to Illustrate Total Body Health 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Improved hCG Diet Helping Patient’s Control Eating Impulses 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Improved hCG Diet Helping Patient’s Control Eating Impulses 3
... ... be conducting a lecture on Radiation Therapy Options For Patients Suffering From Mesothelioma. Her lecture ... ... lecture on Tuesday November 10th, 2009, 5:30 pm CST, MesoCare.org is sponsoring a lecture ...
... SHENZHEN, China, Nov. 6 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited ... of medical devices worldwide, today announced that it will ... Trade Fair with,Congress in Dusseldorf, Germany from November 18-21, ... more than 40 devices from its three core product,segments: ...
... Amex: CVM ), a developer of vaccines and therapeutics ... late-stage oncology company, announced today that an Institutional Review Board ... has given clearance for the Company,s first clinical study to ... study, which will be led by Principal Investigator Jonathan M. ...
... for better motor skills later, study suggests, , THURSDAY, ... of oxygen at birth often go on to have ... can help prevent problems. , Now, a new study ... brain lesions in the babies. , Oxygen starvation ...
... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... ) focused on bringing the life saving potential ... nationwide and internationally, today addressed shareholder questions about its ... S1 with the SEC, in an interview of Matthew ...
... ... almost anyone to sustain life in the first critical minutes of cardiac arrest. ... vital organs alive until professional rescuers arrive. AED (Automated External Defibrillator) is an ... to a normal heartbeat. AEDs are very accurate and easy to use. With ...
Cached Medicine News:Health News:Mindray Medical to Exhibit at MEDICA 2009 in Dusseldorf, Germany 2Health News:CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine 2Health News:CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine 3Health News:Cord Blood America Updates Advantages of Las Vegas Laboratory in Analyst Interview; Explains Recent S1 Filing 2Health News:A New Era of E-Learning in the Comfort and Convenience of Your Home or Office Without the Classroom Environment 2
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... in interbody fusion are to ... restore disc space height and ... an enviroment for bone fusion ... Allograft is designed to promote ...
... highly adaptable and therefore suitable for a ... its extraordinary small outer diameter and the ... a simple but secure and reliable fixation ... instruments around the corner. These characteristics make ...
A new flexible endoscope with an ultra dense optic fiber system. Its two working and irrigation channels and steering mechanism makes it ideal for a multipurpose use in neurosurgical endoscopy i.e. V...
Medicine Products: